Bio-Rad Laboratories
BIO
358.90
-8.60
-2.34%
Bio-Rad Laboratories
US · BIO
#1479 by market cap
Listed 1970
358.90
-8.60
-2.34%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Citi moved from Buy to Hold on 2026-04-07.
Analyst consensus 1 analysts
Buy
Avg price target 440.00 +22.6%
Price target rangecurrent 358.90
Low440.00
Avg440.00
High440.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (14)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-04 | RBC Capital | -- | Buy | 440.00 |
| 2026-09-27 | RBC Capital | -- | Buy | 390.00 |
| 2026-08-06 | RBC Capital | -- | Buy | 390.00 |
| 2026-08-04 | RBC Capital | -- | Buy | 370.00 |
| 2026-05-22 | Wells Fargo | -- | Hold | 310.00 |
| 2026-05-14 | RBC Capital | -- | Buy | 320.00 |
| 2026-05-01 | Wells Fargo | -- | Hold | 290.00 |
| 2026-04-07 | Citi | -- | Hold | 300.00 |
| 2026-02-16 | Wells Fargo | -- | Hold | 320.00 |
| 2026-02-13 | UBS | -- | Buy | 335.00 |
| 2026-02-12 | Citi | -- | Buy | 375.00 |
| 2025-12-15 | Wells Fargo | -- | Hold | 340.00 |
| 2025-10-30 | Wells Fargo | -- | Hold | 340.00 |
| 2025-10-30 | Citi | -- | Buy | 375.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-04-07 | Citi | Buy → Hold | 300.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | After close | ±8.45% | -2.89% (in line) |
| 2026/Q2 | 2026-08-04 | After close | ±8.42% | +4.50% (in line) |
| 2026/Q1 | 2026-04-30 | After close | ±9.56% | -8.41% (in line) |
| 2025/Q4 | 2026-02-12 | After close | ±10.41% | -12.26% (beat) |
| 2025/Q3 | 2025-10-29 | After close | ±8.35% | -4.65% (in line) |
| 2025/Q2 | 2025-07-31 | After close | ±14.92% | +17.63% (beat) |
| 2025/Q1 | 2025-05-01 | After close | ±8.31% | -1.70% (in line) |
| 2024/Q4 | 2025-02-13 | After close | ±8.13% | -9.53% (beat) |
| 2024/Q3 | 2024-10-30 | After close | ±11.39% | +8.35% (in line) |
| 2024/Q2 | 2024-08-01 | After close | ±8.24% | -1.56% (in line) |
| 2024/Q1 | 2024-05-07 | After close | ±8.07% | -4.16% (in line) |
| 2023/Q4 | 2024-02-15 | After close | ±8.93% | +3.59% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Bio-Rad Laboratories discussion 0 comments